Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
A Multinational, Multicenter, Retrospective, Observational Drug Utilisation Study of Seroquel Extended Release (XR) Prescribed by Psychiatrists as Treatment for Major Depressive Disorder (MDD) in Selected Countries in the European Union (EU)
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of informed consent before initiation of any collection of questionnaire data.
- • Documented clinical diagnosis of Major Depressive Disorder, Single Episode, or Recurrent.
- • Initiation of Seroquel XR for treatment of MDD during the period defining the inception cohort, i.e. from 3 months after launch until the index date (12 months after launch).
- Exclusion Criteria:
- • If participating in any clinical trial during the time from 3 months after launch until the index date, the patient cannot take part in this study.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dortmund, , Germany
Patients applied
Trial Officials
Hans A Eriksson, MD
Study Director
AstraZeneca R&D
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials